Auto-antibodies against 2 glycoprotien and anticardiolipin in systemic lupus erythematosus and primary antiphospholipid syndrome

الملخص EN

Objectives: To define the specificity and value of anti- ?2 -glycoprotein1 (anti-?2-GP1) antibodies and anticardiolipin (ACL) in Systemic Lupus Erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS) patients.

Also, to examine the possible association between anti-?2-glycoprotein1 (anti-?2-GP1) antibodies and anticardiolipin (ACL) and the main clinical manifestations of the Antiphospholipid Syndrome (APS).

Methodology: We studied 34 SLE and 10 (PAPS) patients.

We determined the presence of (ACL) and (anti-?2-GP1) immunoglobulin IgG and IgM.

ACL IgG and IgM were detected separately using commercial ELISA kits.

Anti-?2-GP1 antibodies were detected with ELISA using ?2-GP1.

Patients’ clinical data were reviewed separately.

Results: The specificity for anti-?2-GP1 in APS was 97%, with positive predictive value (PPV) of 58%.

Among the ACL-positive patients, specificity was 90% and PPV 80%.

ACL was significantly associated with venous thrombosis (p<0.05) and fetal loss (p<0.01).

A ?2-GP1 was associated with venous thrombosis (p<0.01) and fetal loss (p<0.05).

Conclusions: This study showed that anti-?2-GP1 antibodies have a higher specificity than ACL in SLE and PAPS patients.

The positive predictive value (PPV) of anti-?2-GP1 was greater in ACL-positive patients than in ACL-negative patients.

The association of anti-?2-GP1 and ACL (IgG and IgM) antibodies with the different clinical manifestations (i.e.

thrombosis and fetal loss) may suggest that more than one mechanism may be involved in the pathogenesis of thrombosis and fetal loss.